ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells. - Wikidata - awgldk - TriplyDB

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

http://www.wikidata.org/entity/Q34047847

about

CAR models: next-generation CAR modifications for enhanced T-cell function Immune Cells in Cancer Therapy and Drug Delivery Chimeric antigen receptor T-cell therapy for solid tumors Different Subsets of T Cells, Memory, Effector Functions, and CAR-T Immunotherapy Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street CAR T Cell Therapy: A Game Changer in Cancer Treatment Novel immunotherapies for hematologic malignancies Using gene therapy to manipulate the immune system in the fight against B-cell leukemias Th17 Cell Plasticity and Functions in Cancer Immunity Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic Smart CARs engineered for cancer immunotherapy β-catenin and PI3Kδ inhibition expands precursor Th17 cells with heightened stemness and antitumor activity.CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.Incorporation of a hinge domain improves the expansion of chimeric antigen receptor T cells.Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice Potential therapeutic strategy for gastric cancer peritoneal metastasis by NKG2D ligands-specific T cells Improving therapy of chronic lymphocytic leukemia with chimeric antigen receptor T cells Chimeric antigen receptor-modified T cells strike back.Targeting O-Acetyl-GD2 Ganglioside for Cancer Immunotherapy.Humanized Mouse Models of Clinical Disease.Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer.Global Manufacturing of CAR T Cell Therapy.Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.The CD28-B7 Family in Anti-Tumor Immunity: Emerging Concepts in Cancer Immunotherapy.Enhancing the efficacy of adoptive cellular therapy by targeting tumor-induced immunosuppression.Chimeric Antigen Receptor T-Cells: New Approaches to Improve Their Efficacy and Reduce Toxicity Chimeric Antigen Receptor (CAR) therapy for multiple myeloma.Dynamic analysis of immune and cancer cell interactions at single cell level in microfluidic droplets.The basics of CAR T design and challenges in immunotherapy of solid tumors - Ovarian cancer as a model.Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.The future of cancer treatment: immunomodulation, CARs and combination immunotherapy.How Chimeric Antigen Receptor Design Affects Adoptive T Cell Therapy.Chimeric Antigen Receptor T cells for B Cell Neoplasms: Choose the Right CAR for You.From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain.Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse.The promise of chimeric antigen receptor T cells (CARTs) in leukaemia.The Principles of Engineering Immune Cells to Treat Cancer.

P2860

Q26745600-5B47FA1F-321D-455D-A16B-B1C1BD892222 Q26747061-4E7CDAAA-77A4-4C77-BC0C-372EA0ADDAC4 Q26750908-687047AC-ACC0-4E98-8708-9201FB73F4A7 Q26752955-3D71811A-7FA1-479E-A8F7-2D5864CB6194 Q26778759-F167FB78-54BF-4F3D-BCAD-27E7DC6541DC Q26799357-0EB96ABE-5E8E-4F9B-9FFF-E60784E77F3A Q26822769-71A39CC1-1E0E-41FD-BDBD-E3745C4ABDF9 Q27004436-A9A43042-0B79-4715-8324-D4E861A6935F Q27011297-CE76C659-04B5-4281-B641-F6EDD2930F06 Q27012901-277A7886-216B-4B90-B0D2-A0FA6CB60F24 Q28075992-296D22DB-E98B-4D91-9EC2-1E77588726BB Q28087236-E30082DD-0F6F-4BAE-8A78-DC804B2369DA Q33578997-A1C7B42B-E5A8-4401-A379-430415055B0B Q33671867-D705522F-15B6-460F-BB1A-E41CAD981AB3 Q34553167-8B810533-ED49-4C1B-A281-9E4A197982AB Q35328354-68BAFDCC-D427-4B81-A30B-A3520D4DF387 Q35689938-393B4321-911C-4DDF-B5FC-47803F970539 Q36028047-69398EA7-983B-4301-9903-EB280D8C3456 Q36212699-6D2319A0-6B1E-4A63-A9D1-7D240B2904FE Q36777093-681A5A9F-ECED-4144-9659-0A79906D2957 Q37040370-169E7E53-379D-4D7C-897B-CC5AD710DDB7 Q37592957-D37512CC-B528-42AD-81A4-84FC121EF77D Q37614202-ED1BCB06-F679-4391-9171-E84950C0A6B2 Q37713686-03990F18-E1E0-4159-BDAA-EBF980DE3355 Q37717884-D8D21AA3-CD73-4FD2-9BAB-EC967786C34F Q38289029-98DFDBEF-F17D-4B0B-A25A-CBA2776D305E Q38304438-54F31E6E-D2BF-40B5-8316-D1BD1A576A57 Q38525024-639BC39A-E9B2-408B-B95E-3E52F0E1B7E9 Q38640367-A064AAE9-5951-4422-A6FD-6EE2CFC1B0E1 Q38704573-E5F4FE8B-C7C7-426B-9553-D1D5B0A4AD01 Q38735074-2EDA2CA3-90E4-4B90-BFCC-3D97BD84CEDE Q38748836-4E93D007-0A2B-4B2E-A9A1-F74114F56660 Q38769271-884C62CD-3680-4BAE-B21E-9A7198A56489 Q38775177-D42EC2F0-8797-47A4-8246-8F7AF2481609 Q38830813-ED2FC1B4-9D26-4586-808E-6739A4BBA30F Q38913549-E76E9827-89F2-41BA-A6BC-3D0CA723C356 Q38951943-0EC72656-F71F-45B1-9956-539E0A987E08 Q38957129-5AC03962-1A05-415C-8740-7951D57279D6 Q39039017-490E1E90-9382-4A50-AAE1-2D1689B30323 Q39130457-5366DD9E-805B-45C2-BAE0-9146C997AE88

P2860

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

http://www.wikidata.org/entity/Q34047847

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@ast

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@en

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@nl

type

label

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@ast

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@en

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@nl

prefLabel

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@ast

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@en

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@nl

P1433

Q34047847-2670786E-F899-4C8C-832F-186CD1E50851

P1476

Q34047847-45A114B2-D7E5-47E2-BB5D-1613C3488614

P2093

Q34047847-0D4AB152-2523-4CDD-BF0D-5C338DFA0B17

Q34047847-15EC209F-8994-4B54-A5F1-F037BA576F7C

Q34047847-19E25424-04B4-4C9E-A898-46013BCB81A3

Q34047847-36E827DD-639E-49A9-84A0-214C347BB34A

Q34047847-601FE267-D0EF-48F0-A1F1-BBA8DCE492DB

Q34047847-620B3BF2-6545-491C-BAF7-87160D07DD16

Q34047847-97875154-21CE-4F65-B7AB-E1E91479E31C

Q34047847-B9AAEBE7-A2B7-4ADF-B490-0B40D15F20DC

Q34047847-BB687A3A-1B28-41EA-83B7-3CDEF037E058

Q34047847-EDC2B6B4-BA9A-40C1-ACF4-AA0B23086B5B

P2860

Q34047847-013DE3E5-B647-4487-AA8A-9B54AABBA0E0

Q34047847-01BF4767-21B4-40FA-9451-1C51F91E906D

Q34047847-07320C24-0D54-4D0C-9750-3D58AC416B42

Q34047847-0B106B1B-12C0-4107-AD49-883A43642B46

Q34047847-0B1C278A-9E77-4A8D-B06D-3C187C92FD93

Q34047847-0CAE6A15-1850-4DB9-B77A-62D2328C77BE

Q34047847-0EB5A8C2-1A11-4648-BD22-0386CCB18F4C

Q34047847-1A9FDC67-E156-45EB-8DE0-996254A686F3

Q34047847-1F0181AD-6F71-4545-81F9-637D062E1B8D

Q34047847-25E620C9-DCD1-40F0-B535-C032084A3548

P304

Q34047847-DF6F31BA-04E6-4B8D-9A5C-EE355345AB6B

P31

Q34047847-566200A8-658E-4D8F-B22A-FBBF40E568FE

P356

Q34047847-37456D03-0FBC-4F57-A325-E8CCE343EC5A

P407

Q34047847-99EC8E75-9227-41A6-BBD3-AFD264141AF6

P433

Q34047847-9F943835-7517-46B7-B72E-116320E18FA5

P478

Q34047847-E681A545-46C4-48CB-9EDA-A2D740239A47

P50

Q34047847-DCC0BB29-4418-4F9F-9D52-4E66C0943242

P577

Q34047847-CE8A2E40-0442-4AAC-8611-DBE051D476B6

P5875

Q34047847-29537D4B-23BD-4B1B-AD00-BB7D5D493ABA

P698

Q34047847-C399221A-6972-497D-904E-AB3E0938088E

P932

Q34047847-5016F7C5-58A6-433C-B262-208D6100A490

P356

BLOOD-2013-10-535245

P1433

P1476

ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells.

@en

P2093

Avery D Posey

http://www.w3.org/2001/XMLSchema#string

Aviv Madar

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

Carmine Carpenito

http://www.w3.org/2001/XMLSchema#string

Jihyun Lee

http://www.w3.org/2001/XMLSchema#string

John Scholler

http://www.w3.org/2001/XMLSchema#string

Matthew J Frigault

http://www.w3.org/2001/XMLSchema#string

Nathalie Scholler

http://www.w3.org/2001/XMLSchema#string

Richard Bonneau

http://www.w3.org/2001/XMLSchema#string

Sonia Guedan

http://www.w3.org/2001/XMLSchema#string

P2860

Modulation of TCR-induced transcriptional profiles by ligation of CD28, ICOS, and CTLA-4 receptors

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Tumor-specific Th17-polarized cells eradicate large established melanoma

IL-17 and Th17 Cells

A human memory T cell subset with stem cell-like properties

A validated regulatory network for Th17 cell specification

A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17

Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

P304

1070-1080

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2013-10-535245

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

124

http://www.w3.org/2001/XMLSchema#string

P50

Shannon E McGettigan

P577

2014-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

263713092

http://www.w3.org/2001/XMLSchema#string

P698

24986688

http://www.w3.org/2001/XMLSchema#string

P932

4133482

http://www.w3.org/2001/XMLSchema#string